Loading
A phase 3 trial of Ivosidenib in sarcomas, run by Servier Bio-Innovation LLC, now recruiting.
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen is a phase 3 interventional study registered as NCT06127407 by Servier Bio-Innovation LLC, with 136 participants planned, started 2024-07-09 and due to reach its primary completion in 2028-02-01. Interventions recorded: Ivosidenib 500mg and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/